Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | ENO1 | P06733 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 3/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681950 | 0.92 | PRKCA (0.46) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL8716409 | 0.82 | PRKCA (0.41) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL6840326 | 0.82 | ALDH1A1 (0.42) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL4482845 | 0.82 | GAA (0.46) | PRKCAALDH1A1BTN3A1POLBGAA | |
| Bis(Pivaloyloxymethyl) Succinate SCHEMBL3123390 | 0.82 | PRKCA (0.41) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL203641 | 0.82 | PRKCA (0.41) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL5534787 | 0.81 | PRKCA (0.43) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL8893353 | 0.80 | PRKCA (0.39) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL7373371 | 0.80 | PRKCA (0.39) | PRKCAALDH1A1BTN3A1POLBGAA | |
| SCHEMBL8893364 | 0.80 | PRKCA (0.44) | PRKCAALDH1A1BTN3A1POLBGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| EP-3932931-B1 | A NEBULIZER COMPRISING A PHARMACEUTICAL COMPOSITION COMPRISING 2'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-117460734-A | Pentacyclic derivatives as Zika virus inhibitors | 吉利德科学公司 | 2024-01-26 | — | — | CN | disclosed |
| US-11787832-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2023-10-17 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-11492353-B2 | Methods and compounds for treating Paramyxoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-2937350-B9 | 1' -substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES INC (US) | 2022-08-17 | — | — | EP | disclosed |
| US-20220227776-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | Copycat Sciences Inc. (US) | 2022-07-21 | — | — | US | disclosed |
| EP-3932931-A1 | A NEBULIZER COMPRISING A PHARMACEUTICAL COMPOSITION COMPRISING 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2022-01-05 | — | — | EP | disclosed |
| US-20210253622-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2021-08-19 | — | — | US | disclosed |
| WO-2004096235-A2 | ANTI-CANCER PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096286-A2 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096285-A2 | ANTI-INFECTIVE PHOSPHONATE CONJUGATES | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| WO-2004096287-A2 | INOSINE MONOPHOSPHATE DEHYDROGENASE INHIBITORY PHOSPHONATE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | GILEAD SCIENCES, INC. | 2004-08-12 | — | — | US | disclosed |
| WO-2004035576-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2004035577-A2 | PRE-ORGANIZED TRICYCLIC INTEGRASE INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2004-04-29 | — | — | WO | disclosed |
| WO-2003090690-A2 | CELLULAR ACCUMULATION OF PHOSPHONATE ANALOGS OF HIV PROTEASE INHIBITOR COMPOUNDS AND THE COMPOUNDS AS SUCH | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
| WO-2003091264-A2 | NON NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253622-A1 | 2'- SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, SLC29A1, RNMT | PRKCA 1410/4885ALDH1A1 2205/4885BTN3A1 2990/4885 |
| US-20040167124-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | PRKCA 4411/4885ALDH1A1 2541/4885BTN3A1 3920/4885 |
| US-11492353-B2 | Methods and compounds for treating Paramyxoviridae virus infections | PNP, RPIA, HPRT1 | PRKCA 1530/4885ALDH1A1 1927/4885BTN3A1 4281/4885 |
| US-20040157804-A1 | Pre-organized tricyclic integrase inhibitor compounds | INTS6, INTS9, MUS81 | PRKCA 4411/4885ALDH1A1 2541/4885BTN3A1 3920/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | PRKCA 1530/4885ALDH1A1 1927/4885BTN3A1 4281/4885 |
| US-12509466-B2 | Methods and compounds for treating paramyxoviridae virus infections | MTAP, PNP, NSUN2 | PRKCA 666/4885ALDH1A1 3254/4885BTN3A1 4120/4885 |
| US-20220227776-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | ACE2, ACE, PNP | PRKCA 1074/4885ALDH1A1 1593/4885BTN3A1 4836/4885 |
| US-11787832-B2 | 2′-substituted carba-nucleoside analogs for antiviral treatment | PNP, RNMT, SLC29A1 | PRKCA 1216/4885ALDH1A1 2277/4885BTN3A1 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.